This phased transition is expected to be fully completed by the first quarter of 2019-20, Sun Pharma said in a filing to the BSE.
“The above-mentioned transition and consequential one-time reduction in sales and profit will impact Sun Pharma’s financial results for the period ended March 31, 2019,” it added.
The regulatory filing further said that “Atlas has completed assignment of its business rights and obligations including those arising from the supply contract with Sun Pharma to a wholly owned subsidiary of Sun Pharma”.
This has no material impact on the profit or loss for the year ended March 31, Sun Pharma said.
In January, Sun Pharma had announced that distribution related to the company’s India domestic formulations business shall be transitioned from Aditya Medisales Ltd to its wholly-owned subsidiary.
It had also announced the settlement of a transaction amounting to Rs 2,238 crore with Atlas Global Trading — with which it had a supply agreement — that had arisen out of a patent litigation settlement over Protonix.
Shares of Sun Pharmaceutical Industries closed at Rs 462.10 per scrip on the BSE, down 0.13 per cent from the previous close. AKT HRS